The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer.

Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

More information: Thierry Andre et al, Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2402141 ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite ...